A retrospective study to determine disproportionally elevated signal of developing severe cutaneous adverse reactions to drugs may in patients treated with atezolizumab as compared to those treated with other drugs
Latest Information Update: 19 Aug 2021
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 19 Aug 2021 New trial record
- 29 Jun 2021 Results presented at the European Association for Clinical Pharmacology and Therapeutics Virtual Meeting 2021